Nasdaq:US$12.20 (+0.04) | HKEX:HK$19.19 (-0.13) | AIM:£1.85 (-0.05)
搜索
新闻档案

通过选择所需的新闻类型，可以获得最新的公告或演示文稿。

请使用 「新闻主题」进一步挑选公告类别。
 

所有公告的全文可以PDF文件的形式下载。为方便起见，某些公告的部分或全部文字内容以网页的方式呈现。如存有任何不一致之处，请以PDF版本为准。

新闻类型
公告及新闻稿
演示文稿
新闻主题
其他业务
监管通知
肿瘤学 / 免疫学
集团
12345678910111213
14
15161718
找到相关结果： 891
公告及新闻稿, 其他业务, 新闻稿 | 2015-12-09

US$105 million Shanghai land compensation agreement
Press Release London: Wednesday, 9 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 joint venture with a subsidiary of Shanghai Pharma
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-12-08

和黄医药启动呋喹替尼以非小细胞肺癌为适应症的III期临床试验
2015年12月8日: 和黄医药今日宣布呋喹替尼（HMPL-013）以晚期非鳞状非小细胞肺癌为适应症的中国III期临床试验（FALUCA）正式启动。呋喹替尼是一种新型高选择性抑制血管细胞内皮生长因子受
阅读更多
查看公告 (PDF)
公告及新闻稿, 集团 | 2015-11-13

Second Public Filing of Registration Statement on Form F‑1 for potential Nasdaq Stock Market Listing
The following includes the text of the Announcement, excluding the appendix. For the complete Announcement, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM
阅读更多
公告及新闻稿, 监管通知 | 2015-11-10

Results of Extraordinary General Meeting
London: Tuesday, 10 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that the ordinary resolution and the special resolution put to its Extraordinary General Meeting held on 10 November 2015 (“EGM”) were
阅读更多
公告及新闻稿, 监管通知 | 2015-11-09

Director's Share Dealing
London: Monday, 9 November 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) hereby makes the following amendments to the "Director's Share Dealing" announcement released on 20 October 2015 subsequent to the notification received from Mr
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-11-06

和黄医药启动索凡替尼在美国的临床试验
2015年11月6日：和黄医药今日宣布启动索凡替尼（HMPL-012）在美国的I期临床试验。该药的美国新药临床研究申请于今年递交并通过，2015年11月4日首位受试者接受给药治疗。此外，和黄医药将
阅读更多
查看公告 (PDF)
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2015-10-30

Sulfatinib clinical results and fruquintinib-savolitinib combination preclinical results to be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference
 Press Release London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present further scientific data on sulfa
阅读更多
公告及新闻稿, 监管通知 | 2015-10-30

Total Voting Rights
London: Friday, 30 October 2015: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) hereby notifies the market that as at 30 October 2015, the issued share capital of Chi-Med consisted of 56,533,118 ordinary shares
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-10-30

和黄医药宣布新型Syk抑制剂HMPL-523治疗免疫疾病的I期临床试验取得成功
2015年10月30日:  和黄医药（上海）有限公司（简称 “和黄医药” ）今日宣布成功完成HMPL‑523的I期临床试验。HMPL-523是针对B细胞受体信号通路中的酪氨酸激酶Syk的新型高选择性小分子抑制剂
阅读更多
查看公告 (PDF)
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-10-23

Proof-of-concept study of fruquintinib in non-small cell lung cancer triggers milestone payment
London: Friday, 23 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourt
阅读更多
公告及新闻稿, 监管通知 | 2015-10-20

Director's Share Dealing
London: Tuesday, 20 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) received notification on 19 October 2015 that Mr Christopher Nash, Independent Non-executive Director, has: purchased jointly with his spouse 4,512 ordi
阅读更多
公告及新闻稿, 监管通知 | 2015-10-19

Awards under Long Term Incentive Plan
London: Monday, 19 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that the Remuneration Committee of Chi-Med today granted conditional awards (the “LTIP Awards”) under the Long Term Incentive Plan (the “LTIP
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2015-10-16

Hutchison China MediTech Limited Files Registration Statement for Potential Nasdaq Stock Market Listing
Press Release London: Friday, 16 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it has publicly filed today a registration statement on Form F-1 (the "Registration Statement") with the United States Securiti
阅读更多
公告及新闻稿, 集团 | 2015-10-16

Shareholders' Circular and Notice of Extraordinary General Meeting
London: Friday, 16 October 2015: Hutchison China MediTech Limited ("Chi-Med”) (AIM: HCM) today announces that, following the announcement that it had publicly filed a registration statement on Form F-1 ("Form F-1 Registration Statement") with the U
阅读更多
公告及新闻稿, 集团 | 2015-10-16

Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing
The following includes the text of the Announcement but excludes the appendix. For the complete release, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2015-10-13

Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma
Press Release London: Tuesday, 13 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, and AstraZeneca AB (publ) (“AstraZeneca”) ha
阅读更多
公告及新闻稿, 监管通知 | 2015-10-12

Holding(s) in Company
For filings with the FCA include the annex   For filings with issuer exclude the annex     TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi     1. Identity of the issuer or t
阅读更多
公告及新闻稿, 集团 | 2015-10-08

Winner of International Company of the Year 2015, AIM
At the 2015 AIM Awards, Chi-Med was awarded the title of International Company of the Year. The AIM Awards look at how companies and individuals harness AIM to power their growth and fulfil their strategy. The AIM Awards scrutinises recent joiners
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-09-14

和黄医药将在2015欧洲癌症大会公布呋喹替尼治疗结直肠癌的II期临床研究结果
2015年9月14日：和黄医药今日宣布将在2015年9月25日至29日于奥地利维也纳举行的欧洲癌症大会上公布呋喹替尼治疗转移性结直肠癌临床II期概念验证性试验的详细研究结果。 呋喹替尼是一种
阅读更多
查看公告 (PDF)
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-09-02

呋喹替尼第二个概念验证性临床研究达到主要终点
2015年9月2日: 和黄医药今日宣布呋喹替尼以晚期非鳞状非小细胞肺癌（NSCLC）为适应症的第二个概念验证性（POC）临床研究成功达到主要终点。研究结果显示该试验成功地达到了无进展生存期
阅读更多
查看公告 (PDF)
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-08-19

和黄医药与杨森制药终止HMPL-507项目相关的合作协议
2015年8月19日星期三：和黄医药今日宣布收到杨森制药(Janssen Pharmaceutical, Inc.)关于终止HMPL-507项目的合作研发协议的决定。 和黄医药与杨森制药于2008年开始战略合作，并于2010年修订了合作协
阅读更多
查看公告 (PDF)
公告及新闻稿, 集团 | 2015-07-28

Interim Results for the Six Months Ended 30 June 2015
For the complete release, please download the PDF. --- Drug R&D Division - our Innovation Platform: enrolling 17 clinical trials (H1 2014: 10), with 24 targeted by year-end. China Healthcare and Consumer Products Divisions - our Commercial
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-07-23

Mitsui exchanges its shares in Hutchison MediPharma for shares in Chi-Med
London: Thursday, 23 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that it has signed a subscription agreement (the "Agreement") and completed the exchange of 5,247,493 convertible preference shares held by Mitsui
阅读更多
公告及新闻稿, 其他业务 | 2015-07-17

20-year invention patent granted on Chi-Med's best selling prescription drug
London: Friday, 17 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL"), its prescription drug joint venture, has been granted an invention patent in China ("Inven
阅读更多
公告及新闻稿, 监管通知 | 2015-07-06

Notice of Announcement of 2015 Interim Results
London: Monday, 6 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) will be announcing its interim results for the six months ended 30 June 2015 on Tuesday, 28 July 2015. An analyst presentation will be held at 9:00 am on the same d
阅读更多
公告及新闻稿, 监管通知 | 2015-06-29

Blocklisting Six Monthly Return
London: Monday, 29 June 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM)announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-06-01

和黄医药在2015年度ASCO大会上公布沃利替尼 (AZD6094) Ib期肺癌临床数据
2015年6月1日: 和黄医药今日宣布，其合作伙伴阿斯利康公布了由和黄医药自主研发的c-Met抑制剂沃利替尼（AZD6094）与阿斯利康的候选药物AZD9291联合用药治疗非小细胞肺癌的Ib期临床试验的初
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-05-13

呋喹替尼首个概念验证性临床研究成功，和黄医药获得1800万美元里程碑付款
星期二，2015年5月12日：和黄中国医药科技有限公司今日宣布呋喹替尼以转移性结直肠癌为适应症的首个概念验证性（POC）临床研究达到预期终点，成功触发第一个里程碑，和黄医药将于2015
阅读更多
查看公告 (PDF)
公告及新闻稿, 监管通知 | 2015-04-30

Total Voting Rights
London: Thursday, 30 April 2015: For information purposes, Chi-Med hereby notifies the market that as at 30 April 2015, the issued share capital of Chi-Med consisted of 53,299,964 ordinary shares of US$1.00 each, with each share carrying one right to
阅读更多
公告及新闻稿, 监管通知 | 2015-04-24

Results of Annual General Meeting
London: Friday, 24 April 2015: Chi-Med today announces that all ordinary resolutions and special resolution put to its Annual General Meeting ("AGM") held on 24 April 2015 were duly passed. Please download the PDF.  
阅读更多
公告及新闻稿, 监管通知 | 2015-04-22

Director's Shareholding
London: Wednesday, 22 April 2015: Chi-Med received notification on 22 April 2015 that Mr Christopher Nash, Independent Non-executive Director, has purchased 1,388 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP18.00 pe
阅读更多
公告及新闻稿, 监管通知 | 2015-04-16

Director's Shareholding
London: Thursday, 16 April 2015: Chi-Med received notification on 16 April 2015 that Simon To, Executive Director and Chairman, has purchased 28,000 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP15.85 per share on 15
阅读更多
公告及新闻稿, 监管通知 | 2015-04-13

Director's Shareholding
London: Monday, 13 April 2015: Chi-Med received notification on 13 April 2015 that Simon To, Executive Director and Chairman, has purchased 25,000 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP14.215 per share on 10 A
阅读更多
公告及新闻稿, 监管通知 | 2015-04-08

Directors' Shareholding
London: Wednesday, 8 April 2015: Chi-Med received notifications on 8 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:- Director Date of purchase
阅读更多
公告及新闻稿, 监管通知 | 2015-04-01

Exercise of Options
London: Wednesday, 1 April 2015: Chi-Med announces that it has issued 64,038 ordinary shares of US$1.00 each (the "Shares") following the exercise of options by Mr Johnny Cheng, Executive Director and Chief Financial Officer of Chi-Med, at an exercis
阅读更多
公告及新闻稿, 监管通知 | 2015-04-01

Directors' Shareholding
London: Wednesday, 1 April 2015: Chi-Med received notifications on 1 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the "Shares") as follows:- Director Date of purchase Numbe
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-03-30

呋喹替尼的首个概念验证性（POC）临床研究达到主要疗效终点
2015年3月30日：和黄医药今日宣布呋喹替尼以转移性结直肠癌为适应症的首个概念验证性（POC）临床研究成功达到主要试验终点。研究结果显示该试验成功地达到了无进展生存期的主要疗效终
阅读更多
查看公告 (PDF)
公告及新闻稿, 监管通知 | 2015-03-23

2014 Annual Report and Notice of Annual General Meeting
London: Monday, 23 March 2015: Chi-Med today announces that its 2014 Annual Report together with the Notice of Annual General Meeting and the Proxy Form have been posted to shareholders. The documents can be accessed from the website of Chi-Med (www.
阅读更多
公告及新闻稿, 监管通知 | 2015-03-18

TR-1: Notification of major interest in shares
公告及新闻稿, 肿瘤学 / 免疫学 | 2015-03-06

呋喹替尼治疗非小细胞肺癌的II 期临床试验完成受试者入组；治疗非小细胞肺癌、结直肠癌和胃癌的四项临床研究进展迅速
2015年3月6日，周五：和黄医药今日宣布呋喹替尼（HMPL-013）以非小细胞肺癌为适应症的中国II期临床试验完成受试者入组。呋喹替尼是和黄医药独立研发的血管细胞内皮生长因子受体（VEGFR）
阅读更多
查看公告 (PDF)
公告及新闻稿, 集团 | 2015-02-26

Final Results for the year ended 31 December 2014
For the complete release, please download the PDF. -- Break-out year for Drug R&D Division with 16 clinical studies on 7 drug candidates; 10 potential Breakthrough Therapy indications; as well as record China Healthcare Division revenues and
阅读更多
公告及新闻稿, 其他业务, 新闻稿 | 2015-01-29

Hutchison Sinopharm and AstraZeneca China signed an exclusive distribution agreement on Seroquel® in China
Press Release -  London: Thursday, 29 January 2015: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm"),
阅读更多
公告及新闻稿, 监管通知 | 2015-01-26

Notice of Announcement of 2014 Final Results
London: Monday, 26 January 2015: Chi-Med will be announcing its final results for the year ended 31 December 2014 on Thursday, 26 February 2015. An analyst presentation will be held at 9:00 am on the same day at Citigate Dewe Rogerson, 3 London Wall
阅读更多
公告及新闻稿, 监管通知 | 2014-12-31

Total Voting Rights
公告及新闻稿, 监管通知 | 2014-12-29

Blocklisting Six Monthly Return
公告及新闻稿, 肿瘤学 / 免疫学 | 2014-12-15

呋喹替尼治疗结直肠癌的III期临床试验（FRESCO）启动
2014年12月15日: 和记黄埔医药今日宣布呋喹替尼（HMPL-013）以结直肠癌为适应症的中国III期临床试验（FRESCO）正式启动。呋喹替尼是一种新型高选择性抑制血管细胞内皮生长因子受体（VEGFR）
阅读更多
查看公告 (PDF)
公告及新闻稿, 监管通知 | 2014-11-20

Director's Shareholding
公告及新闻稿, 监管通知 | 2014-10-31

Total Voting Rights
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2014-10-07

Drug R&D Update Briefing for Analysts and Investors on 17 October 2014
Press Release -  London: Tuesday, 7 October 2014:  Chi-Med today announces that it will host a briefing to update analysts and investors on Hutchison MediPharma Limited (“HMP”), its majority owned pharmaceutical R&D division, in London o
阅读更多
公告及新闻稿, 其他业务, 新闻稿 | 2014-10-01

Chi-Med and Merck Serono sign co-promotion agreement
Press Release -  London: Wednesday, 1 October 2014: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Chi-Med, through its subsidiary Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company L
阅读更多
12345678910111213
14
15161718